Biotech Values

[gofishmarko]

>> Patient follow-up ended at three years, so the above is not a reason to wait. <<

Thanks.

re: IDIX -- I have to think the current run is at least partially due to the Stansberry pump. Don't get me wrong , I'll take any run , for any reason , and I think the closer we get to telbivudine approval the more support we'll get.

The Stansberry pre-pumps are usually pretty transparent as to the company they're about to tout. It seems that it might be a decent strategy to invest on the pre-pump, assuming you can guess the company correctly , and then dump fairly early on the pump-pump. I'd also guess that many of his picks would also be good short candidates after the main run.

Might make a good iHub board :

"Stansberry Pre-Pump Pump'N Dumps"